Kidney cancer combo study pulled before it began
NCT ID NCT05487859
First seen Feb 18, 2026 · Last updated May 13, 2026 · Updated 11 times
Summary
This study aimed to see if adding the diabetes drug acarbose to standard immunotherapy was safe and could help control advanced kidney cancer. It planned to enroll people with metastatic renal cell carcinoma. However, the study was withdrawn before any participants were enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.